It seems that there would soon be a vaccine for ovarian cancer as it has been said by a team of researchers lead by Brad Nelson, a molecular and cellular biologist and project leader of the research at the B. C. Cancer Agency's Deeley Research Centre, that the coming three to five years are too crucial for the revelation of the cure of the disease which is by and large a medical anomaly for medical fraternity. As of now, the treatment involves surgery followed by chemotherapy. There are cases where patients start responding to the treatment in the next two or three years but there are significant chances of it being reappearing in the time to come.

The team as of now is working to develop a therapeutic vaccine that could be given after surgery and chemotherapy so that the lost immunity of the body after the initial treatment can be further regained, thereby escalating chances of one’s survival. The team is told to be using a DNA profile of the patient's tumours to develop the vaccine. Funded by Genome B. C, the research has certainly raised hopes of millions of patients across the world.

The approach has been highly influenced by DNA sequencing and there are expectations that this could change the face of medical science in the time to come. If reports from to Ovarian Cancer Canada are to be believed, there are over 2,600 Canadian women who battle with the disease every year and subsequently, 1,750 die of the same.

It has been said many a times by researchers that patients must share their concerns about any change in their body with doctors. It could play significant role in escalating chances of early diagnoses. Even there are hurdles involved in ascertaining the symptoms of the disease which make it more imperative to address the concern of millions of patients suffering from it.